In this study, we investigated the therapeutic efficacy of ADAPT6-ABD-mcDM1 in mice bearing HER2-expressing SKOV3 ovarian cancer xenografts and compared it with a non-targeting homologous construct (ADAPTNeg-ABD-mcDM1) and a vehicle control. Here, ERBB2 is linked to ovarian cancer.